Last reviewed · How we verify
Magnesium aluminum hydroxide
Magnesium aluminum hydroxide is an antacid that neutralizes gastric acid by reacting with hydrochloric acid in the stomach to form water and neutral salts.
Magnesium aluminum hydroxide is an antacid that neutralizes gastric acid by reacting with hydrochloric acid in the stomach to form water and neutral salts. Used for Heartburn and acid indigestion, Gastric acid relief.
At a glance
| Generic name | Magnesium aluminum hydroxide |
|---|---|
| Sponsor | Isfahan University of Medical Sciences |
| Drug class | Antacid |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
This combination antacid works through a dual mechanism: aluminum hydroxide and magnesium hydroxide both act as bases that directly neutralize excess stomach acid, raising gastric pH and providing symptomatic relief of acid-related conditions. The formulation combines these two hydroxides to balance efficacy while minimizing individual side effects (aluminum tends to cause constipation while magnesium tends to cause diarrhea).
Approved indications
- Heartburn and acid indigestion
- Gastric hyperacidity
- Peptic ulcer disease (symptomatic relief)
Common side effects
- Constipation
- Diarrhea
- Nausea
- Abdominal cramping
Key clinical trials
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2, PHASE3)
- Famotidine and Antacids for Treatment of Dyspepsia (PHASE4)
- Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients (PHASE4)
- Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders (PHASE2)
- Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders (PHASE2)
- COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 (PHASE3)
- PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects (PHASE1)
- Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnesium aluminum hydroxide CI brief — competitive landscape report
- Magnesium aluminum hydroxide updates RSS · CI watch RSS
- Isfahan University of Medical Sciences portfolio CI